ArticleMolecular pharmaceutics2011
A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo.
Article in Molecular pharmaceutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- Water-Soluble Nanoconjugate for Enhanced Cellular Delivery of Receptor-Targeted Magnetic Resonance Contrast Agents.Bioconjugate chemistry · 2019Article
- Gd(III)-Dithiolane Gold Nanoparticles for T1-Weighted Magnetic Resonance Imaging of the Pancreas.Nano letters · 2016Article
- Cell-Permeable Esterase-Activated Ca(II)-Sensitive MRI Contrast Agent.Bioconjugate chemistry · 2016Article
- Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.Frontiers in oncology · 2016Article
- Multimeric Near IR-MR Contrast Agent for Multimodal In Vivo Imaging.Journal of the American Chemical Society · 2015Article
- Nanodiscs as a Modular Platform for Multimodal MR-Optical Imaging.Bioconjugate chemistry · 2015Article
- Progesterone-targeted magnetic resonance imaging probes.Bioconjugate chemistry · 2014Article
- Lanthanide probes for bioresponsive imaging.Chemical reviews · 2014Review
- Mechanisms of Gadographene-Mediated Proton Spin Relaxation.The journal of physical chemistry. C, Nanomaterials and interfaces · 2013Article
- Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging.Current molecular imaging · 2012Article
- Analytical methods for characterizing magnetic resonance probes.Analytical chemistry · 2012Article
- Synthesis, Characterization, and in vitro Testing of a Bacteria-Targeted MR Contrast Agent.European journal of inorganic chemistry · 2012Article
- Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers.Bioconjugate chemistry · 2011Article
- Reporter protein-targeted probes for magnetic resonance imaging.Journal of the American Chemical Society · 2011Article
- Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model.Contrast media & molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Progesterone receptor (PR) is a significant biomarker in diseases such as endometriosis and breast, ovarian, and uterine cancers that is associated with disease prognosis and therapeutic efficacy. While receptor status is currently determined by immunohistochemistry assays, the development of noninvasive PR imaging agents could improve molecular characterization, treatment decisions, and disease monitoring. ProGlo, a progesterone-conjugated magnetic resonance imaging (MRI) contrast agent, was evaluated in vivo to determine whether it targets and enhances signal intensity in organs and tumors that express high PR levels. A tissue distribution study indicated that ProGlo accumulates in the PR-rich uterus, which was confirmed by in vivo imaging studies. Ex vivo images of these organs revealed that ProGlo was distributed in the substructures that express high PR levels. In xenograft tumor models, ProGlo was taken up to a greater extent than the nonfunctionalized Gd-DO3A in tumors, particularly in PR(+) tumors. The ability to accumulate and enhance signal intensity in PR(+) organs and tumors suggests that ProGlo may be a promising MRI probe for PR(+) diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.